Endo International PLC Updates Q3 Earnings Guidance

Endo International PLC Updates Q3 Earnings Guidance

Endo International PLC (NASDAQ:ENDP) (TSE:ENL) issued an update on its third quarter earnings guidance on Monday morning. The company provided earnings per share (EPS) guidance of $0.85 for the period, compared to the Thomson Reuters consensus estimate of $0.67. The company issued revenue guidance of $785 million, compared to the consensus revenue estimate of $784.88 million.Endo International PLC also updated its FY17 guidance to $3.35-3.65 EPS.

Endo International PLC (ENDP) opened at $6.09 on Friday. The company has a quick ratio of 0.80, a current ratio of 1.02 and a debt-to-equity ratio of 10.20. The firm has a market cap of $1,359.85, a P/E ratio of 1.23 and a beta of 0.53. Endo International PLC has a 1 year low of $5.77 and a 1 year high of $18.63.

Endo International PLC (NASDAQ:ENDP) (TSE:ENL) last posted its earnings results on Thursday, November 9th. The company reported $0.91 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.85 by $0.06. The firm had revenue of $786.90 million during the quarter, compared to analysts’ expectations of $794.93 million. Endo International PLC had a negative net margin of 126.93% and a positive return on equity of 37.58%. The company’s revenue was down 11.0% compared to the same quarter last year. During the same period in the previous year, the company earned $1.01 earnings per share. research analysts predict that Endo International PLC will post 3.54 EPS for the current year.

A number of

analysts have recently weighed in on the stock. Royal Bank Of Canada reduced their price objective on shares of Endo International PLC from $9.00 to $8.00 and set a sector perform rating for the company in a research note on Friday. Cowen and Company reissued a hold rating and issued a $16.00 price target on shares of Endo International PLC in a report on Thursday, August 10th. Oppenheimer Holdings, Inc. reissued a hold rating on shares of Endo International PLC in a report on Tuesday, August 8th. Deutsche Bank AG set a $13.00 target price on shares of Endo International PLC and gave the stock a buy rating in a report on Wednesday, August 9th. Finally, BMO Capital Markets reiterated a market perform rating and set a $11.00 price target (down previously from $15.00) on shares of Endo International PLC in a research report on Friday, August 11th. Four equities research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and five have issued a buy rating to the company. The company has an average rating of Hold and a consensus target price of $12.58.

In other news, CFO Blaise Coleman purchased 6,500 shares of the business’s stock in a transaction dated Tuesday, August 15th. The shares were purchased at an average cost of $7.89 per share, with a total value of $51,285.00. Following the completion of the purchase, the chief financial officer now owns 13,729 shares of the company’s stock, valued at approximately $108,321.81. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders have bought 16,000 shares of company stock worth $125,460 over the last three months. Insiders own 0.50% of the company’s stock.

About Endo International PLC

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Earnings History and Estimates for Endo International PLC (NASDAQ:ENDP)

Source link


Please enter your comment!
Please enter your name here